Lukas Biomedical Inc

Lukas Biomedical Inc operates with a current liquidity position that is medium in risk, as indicated by a current ratio of 2.19 and a debt-to-equity ratio of 0.35. The company's liquidity is supported by total assets of TWD 476.5 million, but its operating cash flow is negative at TWD -70.5 million, and free cash flow is also negative at TWD -83.9 million. The company's profitability is weak, with a return on equity of -28.97% and a return on assets of -19.81%. These metrics are below the industry median for medical equipment and biotechnology firms, which typically exhibit positive returns. The company reported a net loss of TWD 94.4 million and an operating loss of TWD 92.1 million, indicating significant underperformance relative to its peers. Lukas Biomedical Inc's revenue is derived from multiple segments, including cosmetics, medical equipment leasing, and management consulting. However, the company's financial data does not provide a breakdown of revenue by segment or geography, making it difficult to assess concentration risk or geographic exposure. The company's growth trajectory is uncertain, as it has reported declining profitability and negative cash flows. The outlook for the current fiscal year does not indicate a reversal of this trend, and there is no clear evidence of revenue growth in the near term. The company's capital expenditures are relatively low at TWD -6.8 million, suggesting limited investment in expansion or innovation. The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a low probability of dilution, but the company's negative net cash position after subtracting total debt raises concerns about its ability to meet short-term obligations. The company has not disclosed any recent events or filings that would suggest a material change in its risk profile. There are no recent events or filings disclosed that would suggest a material change in the company's operations or financial position. The company's financial statements do not indicate any significant developments in the past quarter that would impact its valuation or risk profile.